NASDAQ: ICLRIcon PLC Stock
$149.31+4.31 (+2.97%)
Updated Apr 29, 2025
Icon shares are trading lower... find out Why ICLR Price Moved with a free WallStreetZen account
Why Price MovedICLR Price
$149.31
Fair Value Price
N/A
Market Cap
$12.06B
52 Week Low
$133.28
52 Week High
$347.72
P/E
15.55x
P/B
1.27x
P/S
1.72x
PEG
0.76x
Dividend Yield
N/A
Revenue
$8.28B
Earnings
$758.19M
Gross Margin
29%
Operating Margin
13.36%
Profit Margin
9.6%
Debt to Equity
0.77
Operating Cash Flow
$1B
Beta
1.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ICLR Overview
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ICLR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
ICLR
Ranked#29 of 44
Ranked#29 of 44
Be the first to know about important ICLR news, forecast changes, insider trades & much more!
ICLR News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ICLR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ICLR ($149.31) is trading above its intrinsic value of $123.87, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ICLR is good value based on its earnings relative to its share price (15.55x), compared to the US market average (29.19x)
P/E vs Market Valuation
ICLR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more ICLR due diligence checks available for Premium users.
Valuation
ICLR fair value
Fair Value of ICLR stock based on Discounted Cash Flow (DCF)
Price
$149.31
Fair Value
$295.04
Undervalued by
49.39%
ICLR ($149.31) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ICLR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
15.55x
Industry
38.53x
Market
29.19x
ICLR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ICLR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ICLR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.27x
Industry
3.38x
ICLR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ICLR price to earnings growth (PEG)
For valuing profitable companies with growth potential
ICLR is good value based... subscribe to Premium to read more.
PEG Value Valuation
ICLR's financial health
Profit margin
Revenue
$2.0B
Net Income
$154.2M
Profit Margin
7.7%
ICLR's Earnings (EBIT) of $1.11B... subscribe to Premium to read more.
Interest Coverage Financials
ICLR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$16.7B
Liabilities
$7.2B
Debt to equity
0.76
ICLR's short-term assets ($3.53B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ICLR's long-term liabilities ($4.56B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ICLR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ICLR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$268.2M
Investing
-$37.3M
Financing
-$252.8M
ICLR's operating cash flow ($1.29B)... subscribe to Premium to read more.
Debt Coverage Financials
ICLR vs Diagnostic & Research Stocks
Icon Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.